Diagnostics informing treatment of drug resistant infections and cancer.

15 September 2017, 3pm - 4pm
Rountree Room 356, Level 3, Biological Sciences Building D26

Diagnostics informing treatment of drug resistant infections and cancer.

Event details

When:
15 September 2017, 3pm - 4pm
Where:
Rountree Room 356, Level 3, Biological Sciences Building D26
(Map Ref D26)
Event type:
Seminar
Event open to:
Everyone
Booking is not necessary
 
Molecular diagnostics are transforming clinical practice from empirical to precise. Dr Alison Todd's career has been focused on the realization of this. She is the co-founder of SpeeDx, an Australian Diagnostics company whose activities transverse technology invention, clinical test development and international distribution. SpeeDx's IVD menu includes tests for STDs and antibiotic resistance status, and its technologies have been out-licensed to Biocartis for use in companion diagnostics for cancer.